Literature DB >> 6270215

Antistaphylococcal activity of rifampin with other antibiotics.

S H Zinner, H Lagast, J Klastersky.   

Abstract

The bactericidal activity of rifampin plus other antibiotics was examined with in vitro checkerboard dilutions against 15 strains of staphylococci, with time-kill studies, and with determinations of serum bactericidal activities (SBAs) in volunteers. In vitro synergism was found consistently only in inhibitory assays with rifampin plus minocycline. Time-kill studies with rifampin plus methicillin revealed enhanced killing at concentrations close to the MBC but reduced combined activity at higher concentrations. SBAs with rifampin, oxacillin, and the two drugs in combination were studied in three treatment regimens (regimen A: 2 g of oxacillin and 300 mg of rifampin; regimen B: 1 g of oxacillin and 450 mg of rifampin; and regimen C: 3 g of oxacillin and 450 mg of rifampin). The SBA against methicillin-sensitive Staphylococcus aureus was significantly lower with the two drugs in combination than with oxacillin alone in regimen A but not in regimen B. In vitro synergy with rifampin plus other antibiotics was not frequent. At high concentrations, the bactericidal activity of oxacillin was reduced by rifampin, but killing activity may be enhanced at low concentrations of oxacillin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6270215     DOI: 10.1093/infdis/144.4.365

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  25 in total

1.  In vitro interaction between rifampin and clindamycin against pathogenic coagulase-negative staphylococci.

Authors:  M Arditi; R Yogev
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

2.  Vancomycin for treatment of infections with methicillin-resistant Staphylococcus aureus: are there alternatives?

Authors:  D Milatovic
Journal:  Eur J Clin Microbiol       Date:  1986-12       Impact factor: 3.267

3.  In vitro antimicrobial effect against Streptococcus pneumoniae of adding rifampin to penicillin, ceftriaxone, or 1-ofloxacin.

Authors:  K P Giron; M E Gross; D M Musher; T W Williams; R A Tharappel
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

4.  Failure of time-kill synergy studies using subinhibitory antimicrobial concentrations to predict in vivo antagonism of cephalosporin-rifampin combinations against Staphylococcus aureus.

Authors:  C M Brandt; M S Rouse; B M Tallan; W R Wilson; J M Steckelberg
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

Review 5.  Antimicrobial susceptibility of coagulase-negative staphylococci.

Authors:  G L Archer; M W Climo
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

6.  In vitro activity of rifampin in combination with oxacillin against Staphylococcus aureus.

Authors:  M Maduri Traczewski; D A Goldmann; P Murphy
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

7.  Use of rifampin in persistent coagulase negative staphylococcal bacteremia in neonates.

Authors:  N Margreth van der Lugt; Sylke J Steggerda; Frans J Walther
Journal:  BMC Pediatr       Date:  2010-11-19       Impact factor: 2.125

8.  Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.

Authors:  S M Palmer; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

9.  Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.

Authors:  S L Kang; M J Rybak; B J McGrath; G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

10.  Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections.

Authors:  P Van der Auwera; J Klastersky; J P Thys; F Meunier-Carpentier; J C Legrand
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.